Phase 2 study with Baker's Antifol in solid tumors
One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal c...
Gespeichert in:
| Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 1977-04, Vol.37 (4), p.980 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | 980 |
| container_title | Cancer research (Chicago, Ill.) |
| container_volume | 37 |
| creator | Rodriguez, V Richman, S P Benjamin, R S Burgess, M A Murphy, W K Valdivieso, M Banner, R L Gutterman, J U Bodey, G P Freireich, E J |
| description | One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_139205</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>139205</sourcerecordid><originalsourceid>FETCH-LOGICAL-h169t-db1a889d6558b04077d6c2b53c6957584fb2671f835b246e06e453242d87e4ec3</originalsourceid><addsrcrecordid>eNotjrFuwjAUAD2UFkr7Bx28dYpkP_vZzkhRC0hIZaAzsmNHcZsQFDtC_H2RYDrdcroHMmOMmQKlhil5Tun3qsgZPpFHLkpgOCOwa2wKFGjKo7_Qc8wN_bB_YXhPdHHMse5bGo809W30NI9dP6QXMqltm8LrnXPy8_W5X66L7fdqs1xsi4arMhfecWtM6RWicUwyrb2qwKGoVIkajawdKM1rI9CBVIGpIFGABG90kKESc_J2655G1wV_OA2xs8PlcFsX_1vSPFM</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase 2 study with Baker's Antifol in solid tumors</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Rodriguez, V ; Richman, S P ; Benjamin, R S ; Burgess, M A ; Murphy, W K ; Valdivieso, M ; Banner, R L ; Gutterman, J U ; Bodey, G P ; Freireich, E J</creator><creatorcontrib>Rodriguez, V ; Richman, S P ; Benjamin, R S ; Burgess, M A ; Murphy, W K ; Valdivieso, M ; Banner, R L ; Gutterman, J U ; Bodey, G P ; Freireich, E J</creatorcontrib><description>One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.</description><identifier>ISSN: 0008-5472</identifier><identifier>PMID: 139205</identifier><language>eng</language><publisher>United States</publisher><subject>Adenocarcinoma - drug therapy ; Adolescent ; Adult ; Aged ; Carcinoma, Squamous Cell - drug therapy ; Colonic Neoplasms - drug therapy ; Drug Eruptions - etiology ; Female ; Folic Acid Antagonists - administration & dosage ; Folic Acid Antagonists - adverse effects ; Folic Acid Antagonists - therapeutic use ; Head and Neck Neoplasms - drug therapy ; Humans ; Kidney Neoplasms - drug therapy ; Lung Neoplasms - drug therapy ; Male ; Melanoma - drug therapy ; Middle Aged ; Neoplasms - drug therapy ; Rectal Neoplasms - drug therapy ; Remission, Spontaneous ; Sarcoma - drug therapy ; Stomatitis - chemically induced ; Triazines - administration & dosage ; Triazines - therapeutic use</subject><ispartof>Cancer research (Chicago, Ill.), 1977-04, Vol.37 (4), p.980</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/139205$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodriguez, V</creatorcontrib><creatorcontrib>Richman, S P</creatorcontrib><creatorcontrib>Benjamin, R S</creatorcontrib><creatorcontrib>Burgess, M A</creatorcontrib><creatorcontrib>Murphy, W K</creatorcontrib><creatorcontrib>Valdivieso, M</creatorcontrib><creatorcontrib>Banner, R L</creatorcontrib><creatorcontrib>Gutterman, J U</creatorcontrib><creatorcontrib>Bodey, G P</creatorcontrib><creatorcontrib>Freireich, E J</creatorcontrib><title>Phase 2 study with Baker's Antifol in solid tumors</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.</description><subject>Adenocarcinoma - drug therapy</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Drug Eruptions - etiology</subject><subject>Female</subject><subject>Folic Acid Antagonists - administration & dosage</subject><subject>Folic Acid Antagonists - adverse effects</subject><subject>Folic Acid Antagonists - therapeutic use</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Melanoma - drug therapy</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Rectal Neoplasms - drug therapy</subject><subject>Remission, Spontaneous</subject><subject>Sarcoma - drug therapy</subject><subject>Stomatitis - chemically induced</subject><subject>Triazines - administration & dosage</subject><subject>Triazines - therapeutic use</subject><issn>0008-5472</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1977</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNotjrFuwjAUAD2UFkr7Bx28dYpkP_vZzkhRC0hIZaAzsmNHcZsQFDtC_H2RYDrdcroHMmOMmQKlhil5Tun3qsgZPpFHLkpgOCOwa2wKFGjKo7_Qc8wN_bB_YXhPdHHMse5bGo809W30NI9dP6QXMqltm8LrnXPy8_W5X66L7fdqs1xsi4arMhfecWtM6RWicUwyrb2qwKGoVIkajawdKM1rI9CBVIGpIFGABG90kKESc_J2655G1wV_OA2xs8PlcFsX_1vSPFM</recordid><startdate>197704</startdate><enddate>197704</enddate><creator>Rodriguez, V</creator><creator>Richman, S P</creator><creator>Benjamin, R S</creator><creator>Burgess, M A</creator><creator>Murphy, W K</creator><creator>Valdivieso, M</creator><creator>Banner, R L</creator><creator>Gutterman, J U</creator><creator>Bodey, G P</creator><creator>Freireich, E J</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>197704</creationdate><title>Phase 2 study with Baker's Antifol in solid tumors</title><author>Rodriguez, V ; Richman, S P ; Benjamin, R S ; Burgess, M A ; Murphy, W K ; Valdivieso, M ; Banner, R L ; Gutterman, J U ; Bodey, G P ; Freireich, E J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h169t-db1a889d6558b04077d6c2b53c6957584fb2671f835b246e06e453242d87e4ec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1977</creationdate><topic>Adenocarcinoma - drug therapy</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Drug Eruptions - etiology</topic><topic>Female</topic><topic>Folic Acid Antagonists - administration & dosage</topic><topic>Folic Acid Antagonists - adverse effects</topic><topic>Folic Acid Antagonists - therapeutic use</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Melanoma - drug therapy</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Rectal Neoplasms - drug therapy</topic><topic>Remission, Spontaneous</topic><topic>Sarcoma - drug therapy</topic><topic>Stomatitis - chemically induced</topic><topic>Triazines - administration & dosage</topic><topic>Triazines - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodriguez, V</creatorcontrib><creatorcontrib>Richman, S P</creatorcontrib><creatorcontrib>Benjamin, R S</creatorcontrib><creatorcontrib>Burgess, M A</creatorcontrib><creatorcontrib>Murphy, W K</creatorcontrib><creatorcontrib>Valdivieso, M</creatorcontrib><creatorcontrib>Banner, R L</creatorcontrib><creatorcontrib>Gutterman, J U</creatorcontrib><creatorcontrib>Bodey, G P</creatorcontrib><creatorcontrib>Freireich, E J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodriguez, V</au><au>Richman, S P</au><au>Benjamin, R S</au><au>Burgess, M A</au><au>Murphy, W K</au><au>Valdivieso, M</au><au>Banner, R L</au><au>Gutterman, J U</au><au>Bodey, G P</au><au>Freireich, E J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase 2 study with Baker's Antifol in solid tumors</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1977-04</date><risdate>1977</risdate><volume>37</volume><issue>4</issue><spage>980</spage><pages>980-</pages><issn>0008-5472</issn><abstract>One hundred thirty-eight adults with advanced cancers were treated with Baker's Antifol. The complete response + partial response rate was only 10%. Best responses were obtained in 31 patients with lung adenocarcinoma (complete response + partial response, 13%), in 25 patients with colorectal carcinoma (partial response, 16%), and in 6 patients with renal cell carcinoma (partial response, 50%). Two partial responses occurred in 15 patients with squamous cancer. No significant responses were seen in 27 patients with other adenocarcinomas, 13 with sarcomas, 14 with melanomas, and 8 with miscellaneous tumors. The most frequent toxicities were dermatitis, stomatitis, gastrointestinal symptoms, and mild myelosuppression. The incidence of dermatitis was significantly decreased by shortening the schedule of Baker's Antifol administration from 5 to 3 days. Baker's Antifol has some degree of antitumor activity, and studies of combination of this agent with other effective chemotherapeutic agents are indicated.</abstract><cop>United States</cop><pmid>139205</pmid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-5472 |
| ispartof | Cancer research (Chicago, Ill.), 1977-04, Vol.37 (4), p.980 |
| issn | 0008-5472 |
| language | eng |
| recordid | cdi_pubmed_primary_139205 |
| source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
| subjects | Adenocarcinoma - drug therapy Adolescent Adult Aged Carcinoma, Squamous Cell - drug therapy Colonic Neoplasms - drug therapy Drug Eruptions - etiology Female Folic Acid Antagonists - administration & dosage Folic Acid Antagonists - adverse effects Folic Acid Antagonists - therapeutic use Head and Neck Neoplasms - drug therapy Humans Kidney Neoplasms - drug therapy Lung Neoplasms - drug therapy Male Melanoma - drug therapy Middle Aged Neoplasms - drug therapy Rectal Neoplasms - drug therapy Remission, Spontaneous Sarcoma - drug therapy Stomatitis - chemically induced Triazines - administration & dosage Triazines - therapeutic use |
| title | Phase 2 study with Baker's Antifol in solid tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T13%3A38%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%202%20study%20with%20Baker's%20Antifol%20in%20solid%20tumors&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=Rodriguez,%20V&rft.date=1977-04&rft.volume=37&rft.issue=4&rft.spage=980&rft.pages=980-&rft.issn=0008-5472&rft_id=info:doi/&rft_dat=%3Cpubmed%3E139205%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/139205&rfr_iscdi=true |